GH Research PLC (GHRS)

GH Research PLC (GHRS) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.3B; returns 1 day -2.3%, 1 week -0.4%, 1 year +36.2%.

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing ultra-rapid acting therapies for psychiatric and neurological disorders, specifically treatment-resistant depression (TRD). The company's primary business model centers on its proprietary mebufotenin (5-MeO-DMT) pipeline, headlined by its lead candidate GH001.

Groups GHRS belongs to

• Clinical Stage Biopharma
• Biotechnology
• Clinical Stage
• Neurological Disorders
• Mental Health Solutions
• Healthcare
• Neuroscience
• Biopharmaceutical
• Healthcare Innovation
• R&D

GHRS financial model: income statement, cash flow and balance sheet